ORKA-001 Psoriasis Drug Shows High Efficacy in Trial
The Phase 2b results show a 61 percent complete clearance rate, clearing the path for Oruka's Phase 3 clinical trials in 2027.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Is now a good time to invest in companies based on early-stage clinical trial results?
Oruka Therapeutics reported positive Phase 2b clinical trial results for its psoriasis drug, ORKA-001. In the trial, 61 percent of patients receiving a 600 mg dose achieved complete skin clearance after 16 weeks.
Why it matters
The successful data marks a critical milestone for Oruka as it moves to engage regulatory agencies for Phase 3 trials. The company aims to enter a competitive biologics market with projected peak global sales of $7 billion.
The Phase 2b Everlast-B trial enrolled 187 patients with moderate-to-severe plaque psoriasis. Participants receiving the 600 mg dose showed an 86 percent PASI 90 score, while treatment-emergent adverse events occurred in 39 percent of high-dose patients compared to 43 percent in the placebo group.
The players
Oruka Therapeutics
A biotechnology company developing biologic therapies for chronic skin diseases.
Guggenheim
An investment firm that maintains a Buy rating and a $200 price target for Oruka stock.
The details
The trial measures efficacy using the Psoriasis Area and Severity Index (PASI), a metric that quantifies the redness, thickness, and scaliness of psoriatic plaques. PASI 90 and PASI 100 refer to a 90 percent and 100 percent reduction in disease severity, respectively. The study tested the drug against a placebo to establish a safety and efficacy profile before moving to late-stage clinical evaluation.
Timeline
June 30, 2026: Reported cash and marketable securities balance of $1.1 billion.
October 26, 2026: Oruka stock rose over 13 percent following the trial data.
December 2026: Expected release of longer-term trial results.
First half of 2027: Scheduled initiation of Phase 3 trials.
The Tech Race
The success of ORKA-001 establishes a new competitive benchmark for Oruka in the crowded landscape of biologic psoriasis treatments. The results directly support the company's transition from mid-stage clinical development to the final phase of regulatory testing.
Patients with moderate-to-severe plaque psoriasis may gain a new treatment option if the drug passes upcoming Phase 3 trials. Market participants should monitor the December 2026 data release for indicators of long-term safety and efficacy.
The takeaway
The strong trial results significantly improve Oruka's position in the immunology market. Watch the December 2026 long-term data release to see if the drug sustains its efficacy profile before the planned 2027 Phase 3 launch.
What happens next
Oruka expects to release longer-term trial results in December 2026 and plans to initiate Phase 3 trials in the first half of 2027.
Further reading
For broader trends in drug development, visit Biotech.
Live Poll
Is now a good time to invest in companies based on early-stage clinical trial results?
